BioLineRx’s Potential Multi Billion Dollar Schizophrenia Drug

By: Stock Market News & Stocks to Watch from StraightStocks

Posted on January 15, 2013 at 01:10 AM EST

BioLineRx's (NASDAQ: BLRX) engages in identifying, in-licensing, and developing therapeutic candidates. Its lead clinical therapeutic candidate under development is BL-1020, which is in Phase II/III clinical trials to improve cognitive function in sc...

Related Stocks:

BIOLINERX SP ADR

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates